US Patent Issued to SHENZHEN OPTIMUM BIOLOGICAL TECHNOLOGY on March 17 for "Crystalline form of CXCR2 antagonist and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,235, issued on March 17, was assigned to SHENZHEN OPTIMUM BIOLOGICAL TECHNOLOGY Co. LTD (Shenzhen, China).

"Crystalline form of CXCR2 antagonist and application thereof" was invented by Feng Gao (Shanghai), Yuan Chen (Shanghai), Peng Zhang (Shanghai) and Yunfu Luo (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "A crystalline form of CXCR2 antagonist, such as Compound 1, is used in preparing a drug for treating CXCR2-related diseases."

The patent was filed on July 10, 2020, under Application No. 17/597,563.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sec...